Who
Rekha Hemrajani
Director
Company insider
Files Form 4 as: Director, MaxCyte; Director, BioAge Labs; Director, LB Pharmaceuticals; Director, ALX Oncology Holdings; Director, Adverum Biotechnologies; President and CEO, Aravive; Officer, Arcus Biosciences.
In numbers
- Trades disclosed
- 39
- Buys
- 3
- Sells
- 1
- Bought
- $158K
- Sold
- $22K
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 25 Mar 2019
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,449 at $0.00 | filing |
| 25 Jun 2025filed 27 Aug 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Sold | $22K10,684 at $2.09 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —50,790 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —29,210 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,400 at $0.00 | filing |
| 2 Dec 2024filed 4 Dec 2024 | ALXO ALX Oncology HoldingsBiotechnology | SEC FORM 4 Bought | $47K30,000 at $1.55 | filing |
| 27 Sep 2024filed 10 Mar 2025 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Bought | $54K3,000 at $18.00 | filing |
| 25 Sep 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | ALXO ALX Oncology Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,200 at $0.00 | filing |
News
BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK) Head-To-Head AnalysisBIOA · themarketsdaily.com · 16 Oct 2026MaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpMXCT · rttnews.com · 14 Oct 2026MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceMXCT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Rekha Hemrajani; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.